Figure 3.
Therapeutic efficacy of mEDA-HPVE7-16 immunotherapy alone or in combination with polyinosinic‐polycytidylic acid (Poly IC) adjuvant in TC-1 P3 (A15)-based tumor model. C57BL/6 mice were challenged subcutaneously (s.c.) with 1×105 TC-1 P3 (A15) tumor cells. Seven days later, when the tumor diameter is above 5 mm, they were treated as indicated (n=8 per group). They were subsequently boosted at day 14. Mice were treated with mEDA-HPVE7-16 protein (3 nmols/mouse)+Poly IC (50 µg/mouse) intratumorally (i.t.) or s.c. Tumor size (average of two perpendicular diameters (mm)) was measured at regular intervals. The ratio of tumor-free mice/total mice is shown at day 90 for each treatment. Mice were sacrificed when tumor diameters reached 18 mm or when warranted based on the health of the animals. Kaplan-Meier plot is depicted for each treatment. Results are representative of two independent experiments. PBS, phosphate-buffered saline.